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Background: Health systems need to optimize the use of resources, especially in high-cost 
diseases as rheumatoid arthritis (RA). We aimed to evaluate the efficiency of using centers of 
excellence (CoE) as a strategy for improving RA treatment in Colombia.
Methods: A cost description analysis was carried out using the standard costing technique. 
We estimated the costs of medical consultations, laboratories, images, and medications for 
RA. Categories of care standards stratified by severity were defined using the disease activity 
score in 28 joints (DAS28). We evaluated the impact, in terms of costs (US dollars), for 
providing RA clinical care for a previously described cohort using the CoE approach. 
Statistical analyses were performed in Microsoft Excel®, and R.
Results: Expenditure on therapeutic drugs increases as the severity of RA increases. Drugs 
represent 53.6% of the total cost for the low disease activity (LDA) stage, 75.2% for 
moderate disease activity (MDA), 88.5% for severe disease activity (SDA) and 97% for 
SDA with biologic treatment (SDA+Biologic). Treating 968 patients would cost US$612,639 
(US$487,978–1,220,160) at baseline, per year. After a year of follow-up at the CoE, treating 
the same patients would cost US$388,765 (US$321,710–708,476), which implies potential 
cost-savings of up to US$223,874 per year.
Conclusion: The strategy of providing clinical care for RA through CoE can save US 
$231.3 per patient-per year. The results of our study show that CoE could greatly impact the 
public policies dealing with treatment of RA in Colombia. Applying the CoE model in our 
country would both improve health outcomes, as well as being more efficient in terms of 
costs.
Keywords: rheumatoid arthritis, treat to target, cost-savings, cost-analysis
Introduction
Rheumatoid arthritis (RA) is a public health challenge around the world.1–3 RA 
is characterized by its chronicity and the progressive loss of joint function.1–3 
This joint damage may occur in the early stages of the disease, and after 2 
years, nearly 75% of the patients may develop joint damage with bone 
erosion.1–3
Health systems face the issue of having to guarantee both maximum care to the 
most people, while still being able to finance all the medical technologies required 
to do so.4,5 Resource shortage brings up challenges for economic and assignment 
efficiency, in the management of health services. To this extent, health systems need 
to design strategies that optimize resource utilization to improve the patient care. 
The principles that should guide the design of health system models are efficiency, 
equity, and effectiveness.4,5
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In upper-middle-income countries such as Colombia, 
despite high health insurance coverage rates,6 there is 
evidence of fragmentation in health care processes,7 espe-
cially in chronic diseases like RA. This leads to increased 
health expenditures for both providers and families, as 
well as worse health outcomes for patients. A possible 
solution for this would be providing highly specialized 
service through what is called a Center of Excellence 
(CoE). A CoE centralizes the management of one, or 
multiple, disease(s) helping to reduce costs and improving 
clinical outcomes.8
Using CoEs for RA as example of clinical manage-
ment, an initiative was suggested by the Pan American 
League of Associations of Rheumatology (PANLAR) to 
overcome the deficiencies of fragmented health systems 
and prioritize more effective RA care.9 In environments 
where health care is fragmented, there are many barriers 
for finding adequate care such as (a) geographical distribu-
tion of the patients, (b) low health insurance coverage, and 
(c) low availability of specialists for the management of 
chronic rheumatoid disease.8,9 Additionally, there is a need 
for standardized measurement parameters to obtain quan-
tifiable clinical results in high-cost rheumatic pathologies 
such as RA. Consequently, in 2010, the first recommenda-
tions on treat-to-target (T2T) were made based on evi-
dence and the opinions of experts.10 In 2014, these 
recommendations were revised and adjusted11; T2T allows 
for measuring the percentage of patients that achieve 
remission, both in individual and group populations.11
In Colombia RA is an important cause of mortality, 
morbidity, and burden of disease; more than 72,000 RA 
patients have high rates of work disability, absenteeism, 
and presenteeism.12,13 This also results in a high economic 
burden for the health systems and families, as it is associated 
with a higher use of health resources and higher costs.2,14
In this study, we present the results of an economic 
evaluation of the efficiency of a Colombian CoE providing 
a comprehensive model of patient-centered care (PCC) for 
RA under the T2T recommendations.
We believe that these results may contribute to the 
discussion about how to provide a better service to patients 
suffering from chronic high-cost pathologies.
Methods
This study is an integral part of the evaluation of the 
efficiency and effectiveness of implementing a CoE for 
the comprehensive clinical management of RA. Results of 
this evaluation were presented in a previous publication;15 
in that study, health outcomes were prospectively collected 
in 968 patients followed-up for 24 months using a treat-to- 
target (T2T) strategy with a patient-centered care (PCC) 
model. Regarding DAS28, there was a statistically signifi-
cant improvement (p < 0.001) in the average DAS28 
comparing at the beginning of the time analysis and after 
24 months, decreasing from 3.1 (SD 1.0) to 2.4 (SD 0.7). 
In all patients, the reduction of disease activity was about 
65% (95% CI, 58–71).15
Here we present the measures of the efficiency of the 
CoE approach using a cost-analysis from the perspective 
of a third payer.16 Methods have been described in the 
previous paper15; in brief, we used the technique of stan-
dard costing17,18 for the regular RA patient care process. 
This method is analogous to the bottom-up approach 
(micro-costing), but has several advantages like allowing 
for the generalization of results obtained in different set-
tings with variable levels of complexity because it does 
not consider structural or indirect costs.19,20
Care Standards of the CoE Model
The suggested CoE model is based on an adaptation of the 
clinical practice guidelines for the management of RA in 
Colombia.13 Care standards for each severity level of RA, 
which are defined by the DAS28 score, involve the use of 
different types and frequencies of health services.15
One patient is reviewed by different medical specialists 
and is subject to several laboratory and imaging tests 
depending on the severity of the disease activity. In addi-
tion, a patient safety program, supplementary to the above 
mentioned services, aimed to prevent adverse events and/ 
or ensure the proper management of them when they occur 
has been put into place.15 Patients receive conventional 
disease-modifying antirheumatic drugs (cDMARDs) and 
biologic medications (bDMARDs), depending on the 
DAS28 and their response to treatment.
Cost-Analysis
We estimated the costs of medical consultations, labora-
tory tests, imaging tests, and pharmacological treatment 
measuring the health care resource utilization recom-
mended in the CoE´s standard protocol by activity level 
of the disease.
Costs were estimated following the recommendations 
from the Economic Assessment Guideline of the Instituto 
de Evaluación Tecnológica en Salud (IETS) of Colombia;21 
IETS (Institute of Technological Evaluation in Health) is the 
economic assessment agency of Colombia, and its mission is 
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to produce information based on evidence in order to con-
tribute to the development of better public and practical 
policies in health care (Law 1438 of 2011).22
Costs of pharmacological treatments were computed 
using official information from the following sources: a) 
Newsletters from the National Commission for Prices of 
Medications, and b) Information from the Drug Price 
Information System (Sistema de Información de Precios 
de Medicamentos, SISMED in Spanish) encompassing 
the period of January to December 2017.23 SISMED 
reports prices (minimum price, average price, maximum 
price, and number of units sold) for each drug allowed to 
be sold in Colombia. For this study, each drug price was 
assigned according to the SISMED reported prices, 
weighing them by the number of units sold in the 
country.21 Costs of laboratory and imaging tests, and 
medical consultations were calculated using the 
Instituto de Seguros Sociales’s price list (Social 
Security price list), adding 30%, as recommended by 
the IETS.21
We evaluated the impact in terms of health and economic 
results after the application of a CoE model in the patient 
cohort selected in a previous publication.15 To achieve this, 
we calculated the potential cost-savings of caring for 
a cohort of patients that was previously analyzed15 at differ-
ent moments in time: baseline, follow-up at month 6, and 
follow-up after a year. This calculation was done by multi-
plying the number of people at each moment and the sever-
ity level by the estimated cost for each of the stages of the 
disease. The statistical analyses were carried out using 
Microsoft Excel® 2016 and R programming.
All costs were reported in United States dollars (US$), 
and using the average exchange rate reported by the Banco 
de la República de Colombia for 2017, which was US$1 = 
$2,951.3 Colombian pesos.24
Ethics
This study was approved by the Institutional Research Board 
of Biomab IPS, act 004–25042017. All patients had pre-
viously signed informed consent for data use. This study did 
not represent risks for the patients according to the Resolution 
8430 of 1993 of the Ministry of Health of Colombia. All data 
that could identify a patient were anonymized.
Results
Baseline characteristics of the analyzed cohort are shown in 
Table 1. Nine hundred sixty-eight patients were included in 
these analyses, 19.8% were men. The median age was 64 
years, and the mean of disease duration was 7.7 years 
(1–52). Table 2 reports the annual healthcare resource utili-
zation and costs of medical consultation, laboratory, and 
imaging tests, per year, according to RA disease activity at 
the CoE. The annual cost of services is 2.1 times greater (US 
$293.8 vs US$141.6) in patients with severe disease activity, 
compared to patients in remission (REM).
The annual costs for the pharmaceutical treatment of 
a RA patient at the CoE through the different stages of the 
disease are presented in Table 3. Figure 1A shows the total 
annual costs of treating a patient at a CoE according to the 
various severity levels present. We observed that 39.9% of 
the costs of a patient in remission are spent on drugs, 37.3% 
on medical consultations, 17.2% on laboratory exams, and 
the rest on imaging. As the severity of the disease increases, 
drug costs represent a higher percentage of the overall costs. 
Among low disease activity (LDA) patients, drugs represent 
53.6%, while medical consultations are 30.1% of the overall 
costs; on the other hand, for moderate disease activity (MDA) 
patients, drugs represent 75.2%, for severe disease activity 
(SDA) patients 88.5%, and for SDA+Biologic patients, drugs 
are 96.7% of the total expenditures (Figure 1B).
At the start of follow-up (n = 968 patients), 41% were in 
REM, 17% in LDA, 38% in MDA, and the remaining 4% 
were in SDA. After 6 and 12 months of care at the CoE, 
Table 1 Main Characteristics of the Studied Patients. N = 968
Characteristics N %
Positive antibodies-anticitrulin (+) 355 36.7
Rheumatoid factor (+) 517 53.4
Rheumatoid factor (-) antibodies-anticitrulin (-) 55 5.7
Rheumatoid factor (+) antibodies-anticitrulin (+) 141 14.6
X-ray (erosions in hands/feet) 410 42.4
Prednisone use 799 82.5
Osteoporosis 188 19.4
Sjögren’s syndrome 48 5.0
Chronic kidney disease 10 1.0
Diabetes mellitus 80 8.3
Arterial hypertension 285 29.4
Men 192 19.8
Age, mean (interquartile range) 64 years (55–71)
Disease duration, mean years (range) 7.7 years (1–52)
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75% and 82% of the patients were in REM/LDA, respec-
tively. Table 4 shows the cost of treating patients according 
to the severity of the disease beginning with a cost at 
baseline of US$612,639 (US$487,978–1,220,160), US 
$466,634 (US$382,140–870,912) at month six, and US 
$388,765 (US$321,710–708,476) after a year of follow- 
up, which implies potential cost-savings of up to US 
$223,874 per year (Figure 2).
Discussion
There are no previous published studies estimating the 
potential cost-savings of caring for RA patients at a CoE 
in Colombia. In addition, there are very few studies cost-
ing RA by disease activity level from middle-income 
countries, like those in Latin America.
Clinical and sociodemographic features, such as sex of 
the cohort, presence of arterial hypertension, and disease 
duration were similar to those reported in other 
studies.25–28 Our main finding was that treating the 968 
patients at the CoE would save 36.5% in the first year of 
enrollment, implying cost-savings of US$223,874 per year 
and US$231.3 per studied patient, equivalent to 87.4% of 
the monthly minimum wage in Colombia in 2018.29 Our 
study also suggests that better health results, expressed by 
comprehensive attention based on T2T strategy, guarantee 
lower health expenditures; increasing the number of 
patients in remission and low disease activity (less expen-
sive severity levels), while reducing the number of patients 
in moderate and severe activity, would lead to 
a considerable reduction in costs for third-party payers.
Other Latin-American studies have shown significant 
changes in the evolution of the disease in settings without 
an integral management care for patients with RA.28,30 
A study conducted in Colombia by Machado-Alba28 
exhibited how patients receiving cDMARDs and 
bDMARDs improved the remission rate from 30.1% to 
42.9% (an increment of 12.8%). In our study, the remis-
sion rate increased from 41% to 64%. This shows that in 
Table 2 Annual Costs of Consultation, Laboratory and Imaging Tests Associated with the Treatment of RA at a CoE
Activity Service Use Frequency Costs
Remission LDA MDA SDA Remission LDA MDA SDA
Consultations $87.9 $99.4 $139.6 $226.6
Rheumatology 4 5 7 12 $45.9 $57.4 $80.3 $137.7
Physiatry 3 3 4 6 $22.1 $22.1 $29.4 $44.1
Psychology 3 3 4 6 $7.3 $7.3 $9.7 $14.6
Occupational and physical therapy 3 3 4 6 $7.9 $7.9 $10.5 $15.7
Nutrition 1 1 2 3 $2.4 $2.4 $4.8 $7.2
Pharmaceutical chemistry 1 1 2 3 $2.4 $2.4 $4.9 $7.3
Laboratory Tests $40.7 $40.7 $54.2 $54.2
Blood test 3 3 4 4 $13.6 $13.6 $18.1 $18.1
ESR 3 3 4 4 $1.9 $1.9 $2.5 $2.5
Creatinine 3 3 4 4 $4.1 $4.1 $5.5 $5.5
Urine test 3 3 4 4 $4.1 $4.1 $5.5 $5.5
ALT-AST- alkaline phosphatase 3 3 4 4 $17.0 $17.0 $22.7 $22.7
Imaging Tests $13.0 $13.0 $13.0 $13.0
Hand X-ray 1 1 1 1 $6.5 $6.5 $6.5 $6.5
Foot X-ray 1 1 1 1 $6.5 $6.5 $6.5 $6.5
Total $141.6 $153.0 $206.8 $293.8
Abbreviations: LDA, low disease activity; MDA, moderate disease activity; SDA, severe disease activity; ESR, erythrocyte sedimentation rate test.
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Colombian rheumatological centers, even without 
a comprehensive model of PCC that functions under the 
T2T recommendations, patients will still improve their 
condition. However, under a CoE model, improvement 
tends to be much greater, thus a greater potential for cost- 
saving is plausible. In Colombia, according to the RA 
patient registry (High Cost of Disease Office or Cuenta 
de Alto Costo - CAC, in Spanish), on average a patient 
with RA received three consultations for rheumatology 
during 2017.12 In contrast, the CoE model will guarantee 
more frequency of consultations with a rheumatologist, 
provide the attention of a multidisciplinary team, and 
assure strict follow-up on laboratories and imaging tests.
In this study, we also estimated direct medical costs of 
RA according to disease activity. In a meta-analysis car-
ried out in 2018 by Hresko et al, when compared with 
studies in other countries, it was found that the average 
direct costs of care including all treatment regimens would 
be $3,723 (95% CI: 2,408–5,762), and for patients receiv-
ing biologic treatment it would be $20,262 (95% CI: 
17,480–23,487),31 much higher than those estimated in 
our study. Also, the level of RA severity is a significant 
contributor to health care costs and the use of biologic 
treatment, as was reported in other settings.32
There are strategies to guarantee the efficiency of 
health systems in the world. Among them are the diag-
nosis-related groups, Pay for Performance (P4P) and 
CoE that apply the T2T strategy for RA based on PCC 
model.33 Previous evidence has shown that involving 
the patient as an individual with unique needs, concerns 
and preferences has an important impact on safety, 
effectiveness and costs.34 Our results prove that the 
CoE strategy would have great impact in terms of public 
Table 3 Annual Costs of RA Treatment by Severity of the 
Disease at a CoE
Drug Dose Cost US$ 
Mean (Min–Max)
Remission $94.1 (71.4–194.8)
Methotrexate 15 mg/week $29.5 (27.8–61.8)
Chloroquine 250 mg/day $10.8 (8.1–19.1)
Prednisolone 5 mg/day $5.0 (4.9–8.1)
Acetaminophen 500 mg 3-times per day $41.7 (25.4–92.3)
Folic acid 1 mg/day $2.4 (2.1–4.5)
Tramadol 10–100 mg/day $4.9 (3.1–9.0)
LDA $177.1 (138.1–320.5)
Methotrexate 20 mg/week $29.5 (27.8–61.8)
Sulfasalazine 500 mg 3 times per day $69.0 (58.2–95.0)
Chloroquine 250 mg/day $10.8 (8.1–19.1)
Prednisolone 5 mg/day $5.0 (4.9–8.1)
Acetaminophen 500 mg 4 times per day $55.5 (33.9–123.0)
Folic acid 1 mg/day $2.4 (2.1–4.5)
Tramadol 10–100 mg/day $4.9 (3.1–9.0)
MDA $628.7 
(366.3–1,980.3)
Methotrexate 25 mg/week $29.5 (27.8–61.8)
Sulfasalazine 500 mg 4 times per day $46.0 (38.8–63.3)
Leflunomide 20 mg/day $130.2 (93.5–1074.1)
Prednisolone 5 mg/day $10.0 (9.7–16.2)





Folic acid 1 mg/day $2.4 (2.1–4.5)
SDA $2261.7 
(2007.3–3597.1)
Methotrexate pre-  
filled syringe
20 mg/week $1708.5 
(1707.7–1741.8)
Leflunomide 20 mg/day $130.2 (93.5–1,074.1)
Prednisolone 5 mg/day $10.0 (9.7–16.2)





Folic acid 1 mg/day $2.4 (2.1–4.5)
SDA+Bio* $8,729.3 
(7,789.6–10,783.2)
Methotrexate 25 mg/week $36.8 (34.8–77.2)
(Continued)
Table 3 (Continued). 








Leflunomide 20 mg/day $130.2 (93.5–1,074.1)





Notes: *SDA+Bio: Severe disease activity using biological treatment. **Biological 
treatment: We estimated the average cost of the following anti-TNFs: adalimumab 
(40mg every/15 days), etanercept (50mg weekly), infliximab (200mg every/8 weeks), 
golimumab (50mg/month), certolizumab (400mg/month).
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policies for the treatment of RA in Colombia. By apply-
ing this model in our country, we would greatly improve 
health outcomes, and be even more efficient with health 
care costs.
This study has some limitations that should be consid-
ered. First, we used standard costing, which considered 
cost of treatment and regulated follow-up of the disease, 
but do not consider aspects such as treatment adherence. 
A
B
Figure 1 Annual costs of caring for a RA patient at a CoE and its percentual distribution. (A) Annual costs of caring for a RA patient. (B) Distribution of the costs of caring 
for a patient by RA severity. 
Abbreviations: LDA, low disease activity; MDA, moderate disease activity; REM, remission; SDA, severe disease activity; SDA+Bio, severe disease activity using biological 
treatment.
Table 4 RA Patient Treatment Costs by Severity of the Disease
Activity Baseline Month 6 Month 12
N (%) Total Cost (Min–Max) N (%) Total Cost (Min –Max) N (%) Total Cost (Min–Max)
REM 396 (41) $93,344 (84,332–133,201) 523 (54) $123,280 (111,378–175,919) 620 (64) $146,144 (132,035–208,547)
LDA 161 (17) $52,354 (46,364–74,801) 201 (21) $65,361 (57,883–93,385) 173 (18) $56,256 (49,820–80,376)
MDA 371 (38) $309,954 (212,604–811,428) 220 (23) $183,800 (126,072–481,170) 162 (17) $135,344 (92,835–354,316)
SDA 40 (4) $156,988 (144,678–200,730) 24 (2) $94,193 (86,807–120,438) 13 (1) $51,021 (47,020–65,237)
TOTAL 968 (100) $612,639 (487,978–1,220,160) 968 (100) $466,634 (382,140–870,912) 968 (100) $388,765 (321,710–708,476)
Abbreviations: LDA, low disease activity; MDA, moderate disease activity; REM, remission; SDA, severe disease activity.
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Nevertheless, we think that it is a good estimation of the 
real cost saved because patients are linked to the CoE, 
which is not common in a health system where care is as 
fragmented as it is in Colombia. In this case, health out-
comes are improved because there is a strict follow-up 
depending on the severity levels of the disease. 
Additionally, it is fair to say this is a conservative estima-
tion of the cost-savings, since the costs shown in the 
national price lists are the prices and rates on which 
hospitals and insurance agencies base their negotiations 
in the country. Another limitation related to standard cost-
ing is its inability to account for variability among 
patients. Standard costing gives a dollar value for the 
attention an “average” patient receives according to proto-
col, which changes depending on their health status. To fix 
this limitation, we reported minimum and maximum costs 
as a proxy of the uncertainty of the analysis.
Additionally, this study did not consider the costs of 
adverse effects of treatment. Some estimates suggest that, 
each year, more than 100,000 patients are hospitalized for 
nonsteroidal anti-inflammatory drugs (NSAIDs)-related 
gastrointestinal (GI) complications alone, with direct 
costs ranging from US$1,800-US$8,500 per patient/hospi-
talization. Moreover, it has been reported that 16,500 
people die annually from these complications. In the 
elderly, the medical costs of adverse GI events associated 
with NSAID use likely exceed US$4 billion per year.35
The present study has several advantages too, one is 
that the costing of the annual follow-up and treatment of 
RA at the CoE was performed based on national price lists 
and institutional market price lists, which make the costs 
representative and comparable to the whole health system.
Cost studies are a central part of the economic assessment 
of health interventions.36–38They allow the economic quan-
tification of the activities required in preventing, tending, and 
caring for a disease.36,39 They are essential because they 
estimate the amount of money that would be saved in the 
absence of the disease, and which could be directed to other 
sectors.37 Moreover, they help make informed decisions in 
public health and they are useful because they allow for 
obtaining the necessary supplies to carry out future complete 
economic evaluations of health technologies.36,38 Our study 
creates new questions and generates new research fields that 
value the cost-effectiveness of CoE models in the long-term 
treatment of chronic and high-cost diseases such as RA. One 
very important question is related to the value of the potential 
savings that could be obtained by treating the, roughly, 
72,000 patients with RA in Colombia12 at a CoE with the 
T2T approach. Our results give enough evidence to help 
answer these types of questions.
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